0000000000384353

AUTHOR

Rudolf A. De Boer

showing 5 related works from this author

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumpti…

2011

Alcohol consumption is a moderately heritable trait, but the genetic basis in humans is largely unknown, despite its clinical and societal importance. We report a genome-wide association study meta-analysis of ∼2.5 million directly genotyped or imputed SNPs with alcohol consumption (gram per day per kilogram body weight) among 12 population-based samples of European ancestry, comprising 26,316 individuals, with replication genotyping in an additional 21,185 individuals. SNP rs6943555 in autism susceptibility candidate 2 gene ( AUTS2 ) was associated with alcohol consumption at genome-wide significance ( P = 4 × 10 −8 to P = 4 × 10 −9 ). We found a genotype-specific expression of AUTS2 in 9…

Netherlands Twin Register (NTR)alcohol consumptionPopulationautismSingle-nucleotide polymorphismGenome-wide association studygenome-wide analysis; epidemiologic; transcriptional expression analysis; alcohol consumption; autismBiologyQuantitative trait locus03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingADDICTIVE BEHAVIORDEPENDENCEGenotype/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_medicineSNPeducationGenotyping030304 developmental biologyGenetics0303 health scienceseducation.field_of_studyMultidisciplinaryepidemiologicMENAlcohol Drinking/genetics; Alcohol Drinking/metabolism; Animals; Drosophila melanogaster/genetics; Drosophila melanogaster/metabolism; European Continental Ancestry Group/genetics; Female; Gene Expression Regulation/genetics; Genome-Wide Association Study; Genotype; Humans; Male; Mice; Nuclear Proteins/biosynthesis; Nuclear Proteins/genetics; Polymorphism Single Nucleotide; Proteins/genetics; Proteins/metabolism; Quantitative Trait HeritableBiological Sciencesmedicine.diseaseGENOTYPES3. Good healthDROSOPHILA/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingAutismtranscriptional expression analysis030217 neurology & neurosurgerygenome-wide analysisProceedings of the National Academy of Sciences of the U.S.A.
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure…

2021

n/a Funding Agencies|Applied Therapeutics; Innolife; Novartis PharmaceuticalsNovartis; Abbott DiagnosticsAbbott Laboratories; AstraZenecaAstraZeneca; AbbottAbbott Laboratories; Boehringer IngelheimBoehringer Ingelheim; Cardior Pharmaceuticals Gmbh; Ionis Pharmaceuticals, Inc.; Novo NordiskNovo Nordisk; RocheRoche Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Swiss Heart Foundation; KTI; European UnionEuropean Commission; University of Basel; University Hospital Basel; Beckman Coulter; BRAHMS; Idorsia; NovartisNovartis; Ortho Clinical Diagnostics; Quidel; SiemensSiemens AG; Singulex; Sphingotec; CardioRenal

medicine.medical_specialtyNT-PROBNPMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemNatriuretic Peptide BrainmedicineMANAGEMENTHumansCardiac and Cardiovascular Systems030212 general & internal medicineNatriuretic PeptidesIntensive care medicineDYSPNEAHeart FailureKardiologibusiness.industryEmergency departmentASSOCIATIONmedicine.diseasePeptide FragmentsEMERGENCY-DEPARTMENT3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEuropeAction (philosophy)Heart failurePeptidesCardiology and Cardiovascular MedicinebusinessAtrial Natriuretic FactorBiomarkers
researchProduct

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

2019

Visual Abstract

0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiac & Cardiovascular Systemsempagliflozinheart failure030204 cardiovascular system & hematologySGLT2i sodium-glucose co-transporter 2 inhibitorHF heart failurePRECLINICAL RESEARCH03 medical and health sciences0302 clinical medicineDM diabetes mellitusDiabetes mellitusInternal medicinemedicineEmpagliflozinMI-HF post-infarct heart failureGlycemicScience & TechnologyEjection fractionbusiness.industryNHE sodium-hydrogen exchangerANN artificial neural networkmedicine.diseaseHFrEF HF with reduced ejection fractionBlockadeXIAPmachine learning030104 developmental biologyMechanism of actionlcsh:RC666-701Heart failureCardiovascular System & CardiologyCardiologyRNAseq RNA sequencingempagtiflozinmedicine.symptomCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineJACC: Basic to Translational Science
researchProduct